CTOs on the Move

TCR2

www.tcr2.com

 
TCR² Therapeutics Inc. is a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer. TCR²`s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while exhibiting lower levels of cytokine release.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.tcr2.com
  • 100 Binney Street Suite 710
    Cambridge, MA USA 02142
  • Phone: 617.949.5200

Executives

Name Title Contact Details
Peter Olagunju
 Chief Technology Officer Profile
Aaron Vernon
 Vice President of Technical Operations Profile

Funding

TCR2 raised $125M on 03/21/2018

Similar Companies

Kereos Inc

Kereos Inc is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

5 PRIME

5 PRIME is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Modis Therapeutics

Modis Therapeutics is a biopharmaceutical company focused on developing disease-modifying therapies for rare genetic diseases with high unmet medical need.

Aviva Labs Inc

Aviva Labs Inc is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alltrna

Alltrna is the first transfer RNA (tRNA) platform company, and our mission is to unlock tRNA biology and pioneer tRNA therapeutics to regulate the protein universe and resolve disease. Founded at Flagship Labs in 2018, Alltrna has mapped tRNA biology to systematically design tRNA medicines and encode a completely new, unifying approach to treating both rare and common human diseases driven by shared genetic mutations. Alltrna`s platform combines internal expertise and proprietary machine learning tools to unlock the entire tRNA biology space. We have an unprecedented opportunity to advance a single tRNA medicine to restore disrupted protein production, regardless of target, for thousands of diseases with the same underlying genetic mutation.